EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials

Justine Himpe, Marjolein Orije iD, Emiel A De Jaeghere iD, Katrien Vandecasteele iD, Hannelore Denys iD

Cancers · 14.01.2026 · 18 (2) · 258

DOI: 10.3390/cancers18020258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.01.2026. Verfasst von Justine Himpe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced endometrial cancer is associated with poor survival. With the advent of molecular classification and novel systemic therapies—including immunotherapy and targeted agents—treatment regimens have become increasingly complex. While these approaches aim to improve survival, they also potentially introduce long-term toxicities and treatment burden, reinforcing the importance of incorporating health-related quality of life (HRQoL) and patient-reported outcomes (PROs) into clinical trials.

Methods

A systematic review was conducted of phase III randomized controlled trials (RCTs) in advanced, recurrent, or metastatic endometrial cancer evaluating systemic treatment registered on ClinicalTrials.gov and published up to 30 November 2025. Extracted data included study characteristics, HRQoL instruments, reporting formats, adherence to CONSORT-PRO, and timing of HRQoL dissemination (relative to primary efficacy reports).

Results

Eight phase III RCTs published between 2020 and 2024 were included. Although HRQoL was consistently designated as a secondary endpoint, reporting within pivotal efficacy publications was limited. Most reports presented mean changes from baseline using the EORTC QLQ-C30, QLQ-EN24, and EQ-5D-5L. None of the primary reports reported time-to-deterioration analyses or the proportions of patients improving/deteriorating. Adherence to CONSORT-PRO was low, with only a minority of items addressed. Dedicated QoL publications were delayed by up to 25 months after primary efficacy reports and typically appeared in journals with lower impact factors.

Conclusions

Despite routine inclusion of HRQoL measures in trial protocols, reporting remains inconsistent, limited in scope, and often delayed. Strengthening adherence to established frameworks is essential to ensure that HRQoL endpoints are predefined, analytically robust, and disseminated alongside efficacy data—particularly in a rapidly evolving therapeutic landscape.

Schlagwörter

Stichwörter der Autor:innen

chemotherapyendometrial cancerimmunotherapyquality of lifetargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
  • Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.
  • Gynecological Pelvic Oncology Network (GYPON), 9000 Ghent, Belgium.
  • Department of Radiation Oncology, Ghent University Hospital, 9000 Ghent, Belgium.

ORCID-Profile: Marjolein Orije, Emiel A De Jaeghere, Katrien Vandecasteele, Hannelore Denys

Zitieren

APA

Himpe, J., Orije, M., De Jaeghere, E. A., Vandecasteele, K., & Denys, H. (2026). Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials. Cancers, 18(2), 258. https://doi.org/10.3390/cancers18020258

Vancouver

Himpe J, Orije M, De Jaeghere EA, Vandecasteele K, Denys H. Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials. Cancers. 2026;18(2):258. doi:10.3390/cancers18020258

BibTeX
@article{Himpe2026,
  author = {Himpe, Justine and Orije, Marjolein and De Jaeghere, Emiel A and Vandecasteele, Katrien and Denys, Hannelore},
  title = {Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {258},
  doi = {10.3390/cancers18020258}
}
Kostenlos starten →